scAAV9-VEGF prolongs the survival of transgenic ALS mice by promoting activation of M2 microglia and the PI3K/Akt pathway

Brain Res. 2016 Oct 1;1648(Pt A):1-10. doi: 10.1016/j.brainres.2016.06.043. Epub 2016 Jul 5.

Abstract

Amyotrophic lateral sclerosis (ALS) is an adult-onset neurodegenerative disease that leads to paralysis and death three to five years after diagnosis in most patients. The disease is incurable, and the mechanism of motoneuron degeneration remains unknown, although research has demonstrated that activated microglia are involved in motor neuron death. Here, we used a simple method to deliver AAV9 virus by direct intrathecal injection and found that scAAV9-VEGF-165 improved the motor performance and prolonged the life span of SOD1-G93A mice. Furthermore, scAAV9-VEGF-165 activated the PI3K/Akt survival pathway and increased the level of Bcl-2, which contributed to the protection of motor neurons. Additionally, scAAV9-VEGF-165 attenuated the expression of classically activated (M1) microglial markers and enhanced the expression of alternatively activated (M2) microglial markers. Taken together, the results of our study suggest that simple, direct intrathecal injection of scAAV9-VEGF-165 may have a curative effect for ALS.

Keywords: Adeno-associated virus; Amyotrophic lateral sclerosis; Microglia polarization; Vascular endothelial growth factor.

MeSH terms

  • Amyotrophic Lateral Sclerosis / metabolism
  • Animals
  • Cell Death
  • Cell Survival
  • Dependovirus
  • Disease Models, Animal
  • Injections, Spinal
  • Mice
  • Mice, Transgenic
  • Microglia / metabolism*
  • Motor Neurons / metabolism
  • Phosphatidylinositol 3-Kinase / metabolism
  • Proto-Oncogene Proteins c-akt / metabolism
  • Vascular Endothelial Growth Factor A / genetics
  • Vascular Endothelial Growth Factor A / metabolism*

Substances

  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Phosphatidylinositol 3-Kinase
  • Proto-Oncogene Proteins c-akt